Finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), has been found to reduce the incidence of heart failure (HF) and rates of cardiovascular death among patients with mildly reduced or preserved ejection fraction. Based on the FINEARTS-HF trial, the drug showed a significant positive impact, shedding light on its potential as a new treatment option for HFmrEF/HFpEF.
SafeLine: A Free Zero Trust Web Application Firewall for 2026
Every type of organization—whether it’s a multinational giant with thousands of employees or a single tech enthusiast running a homelab—needs a web application firewall (WAF).
